Scarica l'app Stockscreener
570.16
0.58%
3.173
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$566.99
Aprire:
$566.99
Volume 24 ore:
90,209
Relative Volume:
0.18
Capitalizzazione di mercato:
$24.18B
Reddito:
$3.17B
Utile/perdita netta:
$1.29B
Rapporto P/E:
21.04
EPS:
27.0947
Flusso di cassa netto:
$1.01B
1 W Prestazione:
-1.97%
1M Prestazione:
-3.08%
6M Prestazione:
+19.67%
1 anno Prestazione:
+86.79%
Intervallo 1D:
$560.23
$572.41
Intervallo di 1 settimana:
$560.23
$584.71
Portata 52W:
$272.12
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
569.77 | 24.07B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
16.61 | 52.36B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.235 | 40.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.91 | 39.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.94 | 32.58B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Underweight |
| 2025-09-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock - Investing.com Nigeria
United Therapeutics (UTHR) Reports TETON Study Results on Nebuli - GuruFocus
United Therapeutics’ Tyvaso meets primary endpoint in IPF trial - Investing.com
Inhaled Tyvaso preserves lung function, cuts IPF risks in trial - Stock Titan
United Therapeutics (UTHR) Remains a Key Holding for Renaissance Technologies - GuruFocus
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics (UTHR) Reports Positive Ralinepag Results in Pulmonary Hypertension Study - GuruFocus
Baidu, Brady And 3 Stocks To Watch Heading Into Monday - Benzinga
Experimental PAH pill ralinepag cuts worsening risk 55% in Phase 3 - Stock Titan
Leuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock (US9113631090): FDA clears first UHeart xenotransplantation trial - AD HOC NEWS
United Therapeutics Corporation $UTHR Stock Position Decreased by Thrivent Financial for Lutherans - MarketBeat
United Therapeutics Corporation Announces Fda Clearance to Proceed with Uheart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics stock (US9113631090): fresh data push at ATS 2026 keeps pipeline in focus - AD HOC NEWS
United Therapeutics (UTHR) Receives FDA Approval for UHeart Clin - GuruFocus
FDA clears first human trial of pig-derived transplant heart - Stock Titan
United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares - MarketBeat
UTHRUnited Therapeutics Corp Stock Price and Quote - Finviz
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
Varda Space and United Therapeutics to test drugs in space microgravity - Новости GxP
Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock By Investing.com - Investing.com Canada
Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock - Investing.com UK
Pacer Advisors Inc. Trims Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Ameritas Advisory Services LLC Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
Varda Space, United Therapeutics to test lung drugs in orbit - qz.com
United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
United Therapeutics director Mesa Nilda sells $150,139 in stock By Investing.com - Investing.com Australia
Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics director Mesa Nilda sells $150,139 in stock - Investing.com
Varda Space, United Therapeutics partner on drug development By Investing.com - Investing.com India
United Therapeutics (UTHR) Partners with Varda Space Industries for Innovative Drug Development - GuruFocus
Varda and United Therapeutics Partner to Crystallize Protein in Space for Rare Lung Disease Therapies - geneonline.com
Varda Space, United Therapeutics partner on drug development - Investing.com India
Could this be the moment that drug manufacturing takes off in orbit? - Ars Technica
Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease - ChartMill
United Therapeutics Corp (UTHR) News, Articles, Events & Latest Updates - Stocktwits
United Therapeutics CFO James Edgemond sells $5.7m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CFO James Edgemond sells $5.7m in stock - Investing.com India
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy - Quantisnow
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference - ChartMill
Pharma CEO's Role In Ex-Exec's Contract Permits Deposition - Law360
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 15 '26 |
Sale |
568.11 |
9,500 |
5,397,077 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 14 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 14 '26 |
Sale |
574.48 |
9,500 |
5,457,566 |
40,513 |
| EDGEMOND JAMES | CFO AND TREASURER |
May 14 '26 |
Option Exercise |
135.42 |
10,000 |
1,354,200 |
28,876 |
| EDGEMOND JAMES | CFO AND TREASURER |
May 14 '26 |
Sale |
574.47 |
10,000 |
5,744,746 |
18,876 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 13 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 13 '26 |
Sale |
578.65 |
9,500 |
5,497,166 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 12 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 12 '26 |
Sale |
578.38 |
9,500 |
5,494,563 |
40,513 |
| Mesa Nilda | Director |
May 12 '26 |
Sale |
581.93 |
258 |
150,139 |
5,028 |
1.21%
3.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):